The development of a new technique for labelling the body’s own transporters – exosomes – could have long term benefits in the treatment of life-threatening medical conditions, including cancer. A team of researchers at Cardiff University’s Schools of Pharmacy and ...
Read More »Labeling Extracellular Vesicles for Nanoscale Flow Cytometry
Extracellular vesicles (EVs), including exosomes and microvesicles, are 30-800 nm vesicles that are released by most cell types, as biological packages for intercellular communication. Their importance in cancer and inflammation makes EVs and their cargo promising biomarkers of disease and cell-free ...
Read More »IBM’s Nano-DLD Technology May Speed Up Cancer Screening Process
IBM scientist Joshua Smith and his team developed a new lab-on-a-chip/nano-DLD technology that can separate biological particles which would be helpful to detect diseases like cancer at an early stage. The researchers at IBM have been working since last three years ...
Read More »Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics
In the past decade, extracellular vesicles (EVs) have emerged as a key cell-free strategy for the treatment of a range of pathologies, including cancer, myocardial infarction, and inflammatory diseases. Indeed, the field is rapidly transitioning from promising in vitro reports ...
Read More »Nanoscale lateral displacement arrays for the separation of exosomes
Deterministic lateral displacement (DLD) pillar arrays are an efficient technology to sort, separate and enrich micrometre-scale particles, which include parasites, bacteria, blood cells and circulating tumour cells in blood. However, this technology has not been translated to the true nanoscale, ...
Read More »Nanomechanical sandwich assay for multiple cancer biomarkers in breast cancer cell-derived exosomes
The use of exosomes as cancer diagnostic biomarkers is technically limited by their size, heterogeneity and the need for extensive purification and labelling. University of Alberta researchers report the use of cantilever arrays for simultaneous detection of multiple exosomal surface-antigens ...
Read More »IBM researchers target exosomes with their lab-on-chip technology to overcome challenges in liquid biopsies
IBM scientists will collaborate with the Icahn School of Medicine at Mount Sinai to test on prostate cancer IBM (NYSE: IBM) scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale ...
Read More »